TY - JOUR
T1 - Chronic sildenafil in men with diabetes and erectile dysfunction
AU - Aversa, Antonio
AU - Bruzziches, Roberto
AU - Vitale, Cristiana
AU - Marazzi, Giuseppe
AU - Francomano, Davide
AU - Barbaro, Giuseppe
AU - Spera, Giovanni
AU - Rosano, Giuseppe M C
PY - 2007/6
Y1 - 2007/6
N2 - Erectile dysfunction frequently represents a neurovascular complication of diabetes mellitus, and it has been calculated that almost 50% of diabetic men will have erectile dysfunction within 6 years after diagnosis. Penile endothelial and smooth muscle cell dysfunction are due to molecular pathway abnormalities (i.e., activation of PKC, increased oxidative stress and over-production of advanced-glycosylation end products). The response rate to oral drug therapies, such as sildenafil, is lower than in most other groups. Because therapeutic alternatives (i.e., intracavernous injections with vasoactive agents) are not curative, clinical trials aimed to demonstrate rehabilitative effects with daily phosphodiesterase type-5 inhibitors are ongoing. If this approach proves successful, it will determine many advantages over the intracavernosal treatment and potentially induce sexual rehabilitation.
AB - Erectile dysfunction frequently represents a neurovascular complication of diabetes mellitus, and it has been calculated that almost 50% of diabetic men will have erectile dysfunction within 6 years after diagnosis. Penile endothelial and smooth muscle cell dysfunction are due to molecular pathway abnormalities (i.e., activation of PKC, increased oxidative stress and over-production of advanced-glycosylation end products). The response rate to oral drug therapies, such as sildenafil, is lower than in most other groups. Because therapeutic alternatives (i.e., intracavernous injections with vasoactive agents) are not curative, clinical trials aimed to demonstrate rehabilitative effects with daily phosphodiesterase type-5 inhibitors are ongoing. If this approach proves successful, it will determine many advantages over the intracavernosal treatment and potentially induce sexual rehabilitation.
KW - Diabetes
KW - Endothelial dysfunction
KW - Erectile dysfunction
KW - Phosphodiesterase type-5
KW - Rehabilitation
UR - http://www.scopus.com/inward/record.url?scp=34548250417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548250417&partnerID=8YFLogxK
U2 - 10.1517/17425255.3.3.451
DO - 10.1517/17425255.3.3.451
M3 - Article
C2 - 17539751
AN - SCOPUS:34548250417
VL - 3
SP - 451
EP - 464
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
IS - 3
ER -